Results 141 to 150 of about 98,807 (272)
Asia-Pacific Journal of Clinical Oncology, EarlyView.This study investigated the real‐world use of CDK4/6 inhibitors in Australian patients with HR+/HER2‐ advanced or metastatic breast cancer, providing data on patient demographics, treatment patterns, and outcomes with palbociclib. ABSTRACT Background There is limited real‐world data on the use of CDK4/6 inhibitors in Australian patients with HR+/HER2 ...
Louise Nott +8 more
wiley +1 more source
Retrospective Study of Hepatotoxicity of Gemcitabine （Gemzar®）as First-line Chemotherapy in Non-Small Cell Lung Cancer [PDF]
, 2007 在非小細胞肺癌（Non-small cell lung cancer）之治療藥物中，gemcitabine（Gemzar®）被使用作為後期（advanced）患者之標準療法用藥之一，和其他細胞毒性（cytotoxic）藥物比較起來，其副作用通常較為輕微。但肝毒性（hepatotoxicity）之發生並不少見（約20~50%），表現多為短暫、無症狀且很快恢復之肝酵素升高，很少會持續惡化；除此之外，近年來，越來越多之案例報告顯示gemcitabine有可能造成嚴重肝毒性，如肝臟靜脈阻塞疾病 ...
Wu, Ying-Hui, 吳盈慧
core
Androgen Receptor Expression in Urothelial Bladder Cancer—A Systematic Review and Meta‐Analysis
ANZ Journal of Surgery, EarlyView.ABSTRACT Background Bladder cancer is a globally prevalent malignancy with a marked male predominance. Over the past decade, the androgen receptor has been investigated as a potential contributor to bladder cancer pathophysiology. Androgen receptor expression is most commonly assessed via immunohistochemistry, but its association with pathological ...
Alex Buckby +3 more
wiley +1 more source
Comparison of gemcitabine monotherapy with gemcitabine and cisplatin combination in metastatic pancreatic cancer: a retrospective analysis [PDF]
, 2018 Purpose: Gemcitabine is among the standard first-line agents for the treatment of metastatic pancreatic cancer. However, as the median survival with gemcitabine monotherapy is 6 months, different combinations are being studied for better, prolonged ...
Engins, Huseyin +15 more
core
British Journal of Pharmacology, EarlyView.Abstract Aim Fluoropyrimidines, including 5‐fluorouracil (5‐FU) and capecitabine, are cornerstone antineoplastic agents for cancer. Case reports suggest that these drugs may be associated with an under‐recognised risk of ischaemic stroke or transient ischaemic attack (TIA).
Sophie Nguyen +12 more
wiley +1 more source
Targeting KRAS for cancer therapy
British Journal of Pharmacology, EarlyView.In recent years, therapeutics targeted against KRAS proto‐oncogene GTPase (KRAS)‐mutant cancers have seen significant progress. Herein we outline the biology and epidemiology of KRAS alterations at the lineage and allele levels, reviewing the clinical evidence for KRASG12C inhibition from the discovery of the recessive switch pocket to sotorasib ...
Jianlong Jia +4 more
wiley +1 more source
Cancer Science, EarlyView.Lysine acetyltransferase 2A (KAT2A) is a transcriptional coactivator and a member of the Histone Acetyltransferase (HAT) family. While altered KAT2A activity has been implicated in various cancers, its role in bladder cancer (BLCA) remains poorly understood.
Wenjie Yang +8 more
wiley +1 more source
Targeting Cell Cycle Vulnerabilities in Cancers: Emerging Strategies for Therapeutic Development
Cancer Science, EarlyView.Dysregulated cell cycle control often involves alternative compensatory pathways in cancers to maintain its robustness but provide unique targetable vulnerabilities. We overview recent insights on cancer‐specific vulnerabilities across the cell cycle and discuss how these can be used to develop new therapeutic strategies.
Nana Kamakura +3 more
wiley +1 more source
The different face of skin‐rash induced by brentuximab vedotin
JDDG: Journal der Deutschen Dermatologischen Gesellschaft, EarlyView.Summary Background: Brentuximab vedotin (BV) is a targeted therapy for CD30‐expressing lymphomas, including Hodgkin lymphoma (HL) and cutaneous T‐cell lymphoma (CTCL). While peripheral neuropathy is the most common adverse event, BV‐induced skin rashes are less frequent and not well characterized.
Alessandro Pileri +11 more
wiley +1 more source
Benign by design: A paradigm shift in cosmetic ingredient development
International Journal of Cosmetic Science, EarlyView.Benign by design strategies enable the creation of biodegradable cosmetic ingredients, reducing environmental persistence while maintaining the intended biological activity. This work compiles design rules and tools to guide the development of more sustainable molecules for the cosmetics industry.
Sandra Mota +3 more
wiley +1 more source